The lysine 27 to methionine mutation of histone H3.3 (H3.3K27M) is detected in over 75% of diffuse intrinsic pontine glioma (DIPG). The H3.3K27M mutant proteins inhibit H3K27 methyltransferase complex PRC2, resulting in a global reduction of tri-methylation of H3K27 (H3K27me3). Paradoxically, high levels of H3K27me3 were also detected at hundreds of genomic loci. However, it is not known how and why H3K27me3 is redistributed in DIPG cells.
Introduction
Diffuse intrinsic pontine glioma (DIPG) is the most aggressive primary malignant brain tumor found in children (Louis et al., 2007) . The median survival time after diagnosis is approximately one year with no cure in sight (Dellaretti et al., 2012) . Recent studies have identified, in about 75% of DIPG cases, a somatic mutation of the H3F3A gene, leading to a lysine 27 to methionine mutation at histone H3 variant H3.3 (H3.3K27M) (Schwartzentruber et al., 2012; Sturm et al., 2012; Wu et al., 2012 Wu et al., , 2014 . In addition, HIST1H3B or HIST1H3C, one of the 13 genes encoding canonical histone H3.1/H3.2, is also mutated with the same K to M changes in a small fraction of DIPG tumors (Castel et al., 2015; Fontebasso et al., 2014; Solomon et al., 2016) .
Introducing the mutation in human or mice can induce tumor formation, indicating that it is a driver of tumorigenesis. Therefore, it is critically important to understand how the histone H3K27M mutation drives tumorigenesis.
H3.3 is a histone H3 variant that differs from H3.1/H3.2 by only four or five amino acid residues (Campos and Reinberg, 2009; Maze et al., 2014; Szenker et al., 2011) . Compared to canonical histone H3.1/H3.2 that are assembled into nucleosomes in a replication-coupled process, histone variant H3.3 is assembled into nucleosomes in a replication independent manner (Ahmad and Henikoff, 2002a; Tagami et al., 2004) . H3.3 plays important roles in a variety of cellular processes. For instance, H3.3 is involved in the epigenetic memory of actively transcribed genes in nuclear transferred Xenopus nuclei (Ng and Gurdon, 2008) . Paradoxically, H3.3 is also important for heterochromatin formation during mouse development Jang et al., 2015; Lin et al., 2013) and during oncogene induced senescence (Duarte et al., 2014; Lee and Zhang, 2016; Rai et al., 2014; Zhang et al., 2007) , as well as for silencing of endogenous retroviral elements in mouse embryonic stem cells (Elsässer et al., 2015) . H3.3 at gene bodies is enriched at actively transcribed genes compared to lowly expressed genes (Ahmad and Henikoff, 2002b; Chen et al., 2013; Deaton et al., 2016) , supporting a role of H3.3 in gene transcription.
H3.3 has also been shown to play a role in DNA replication during replication stress (Adam et al., 2013; Frey et al., 2014) . It is proposed that the context-dependent role of H3.3 in different cellular processes are likely linked to its assembly at distinct chromatin regions by different histone chaperones and regulators (Burgess and Zhang, 2013) .
Like other histone H3 proteins, H3.3 is modified post-transcriptionally via the same enzymes, as very few H3.1 and H3.3 specific enzymes have been reported (Guo et al., 2014; Jacob et al., 2014; Wen et al., 2014) . These modifications, including acetylation and methylation, are associated with and/or regulate different cellular processes (Jenuwein and Allis, 2001 ; Klose and Zhang, 2007; Pokholok et al., 2005; Tan et al., 2011; Turner, 2000) . H3K27 can be acetylated (H3K27ac) by p300/CBP (Suka et al., 2001 ) and this modification marks active enhancers in combination with H3K4 mono-methylation (H3K4me1) (Calo and Wysocka, 2013; Creyghton et al., 2010; Heintzman et al., 2009; Shen et al., 2012) . H3K27 can also be mono-, di-and trimethylated (H3K27me1/me2/me3). H3K27me2/me3, catalyzed by the Polycomb repressive complex2 (PRC2) (Pirrotta, 1998) , is enriched at promoters of silenced genes and plays an important role in the silencing of developmentally regulated genes during cell differentiation Cao et al., 2002; Margueron and Reinberg, 2011; Simon and Kingston, 2013) .
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The H3K27 methyltransferase complex PRC2, which consists of four core subunits, Ezh2, Suz12, EED, and RbAP46/48, methylates nucleosomal histone H3K27. In Drosophila cells, the PRC2 complex is recruited to chromatin through DNA binding proteins to Polycomb response elements (PRE), which contain specific cis-regulatory DNA sequences (Simon et al., 1993) . In human cells, however, consistent PRE elements have not been identified and the core subunits of PRC2 complex do not have DNA sequence specific binding abilities, suggesting that human PRC2 is recruited in a more complex manner than Drosophila PRC2 (Mendenhall et al., 2010; Woo et al., 2010) . Indeed, several mechanisms including protein binding partners, non-coding RNAs as well as coding RNAs have been proposed for the recruitment of PRC2 to specific loci for H3K27 methylation (Kaneko et al., 2013; Kanhere et al., 2010; Khalil et al., 2009; Zhao et al., 2010) . For instance, PRC2 forms a complex with Jarid2, which targets PRC2 to specific loci (Peng et al., 2009; Shen et al., 2009 ). Jarid2, a member of Jumonji (Jmj) family, contains a JmjN domain, a JmjC domain, a zinc finger domain, an RNA-binding region (RBR) and a DNAbinding domain, also called AT-rich interaction domain (ARID). Unlike other members of the Jmj family that catalyze the demethylation of lysine residues, Jarid2 does not contain the conserved residues required for iron and ascorbate binding that are essential for the demethylation activity (Pasini et al., 2010; Takeuchi et al., 2006) . Jarid2 is enriched at CGG-and GA-containing sequences (Peng et al., 2009) , and also binds to long non-coding RNA (lncRNA) through RBR in vivo and in vitro (Kaneko et al., 2014) . For instance, Jarid2 interacts with MEG3 (Rocha et al., 2008) , an lncRNA encoded by the imprinted DLK1-DIO3 locus (Kaneko et al., 2013) . It is likely that Jarid2 targets PRC2 to specific loci through its DNA as well as RNA binding activities. Jarid2 is highly expressed in embryonic stem (ES) cells and is required for mouse embryogenesis, including neural tube formation (Takeuchi et al., 1995) and heart 6 development (Mysliwiec et al., 2011 (Mysliwiec et al., , 2012 . In vitro, Jarid2 enhances the enzymatic activity of PRC2 complex (Sanulli et al., 2015; Son et al., 2013) . As a partner of PRC2, Jarid2 facilitates the recruitment of PRC2 to its target genes, stimulates the H3K27 methyltransferase activity, and plays a role in silencing of key regulatory genes during mouse ES cell differentiation.
We and others have found that the levels of H3K27me3 are reduced dramatically in DIPG cells as well as in any tested cell type or organisms expressing H3.3K27M mutant proteins, including mice and Drosophila (Chan et al., 2013a (Chan et al., , 2013b Herz et al., 2014; Lewis et al., 2013) . Several lines of evidence support the idea that the global reduction of H3K27me3 in DIPG cells is due to inhibition of PRC2 by H3.3K27M mutant proteins. In vivo, Ezh2 was enriched at H3.3K27M mono-nucleosomes isolated from cells (Bender et al., 2013; Chan et al., 2013b) . In vitro, PRC2 complex binds to H3.3K27M peptides with high affinity (Justin et al., 2016; Lewis et al., 2013) , and H3.3K27M peptides or mononucleosomes inhibit the enzymatic activity of PRC2 complex (Bender et al., 2013; Jayaram et al., 2016; Jiao and Liu, 2015; Justin et al., 2016) . The crystal structure of H3K27M peptide-PRC2 complex reveals that the H3K27M peptide binds to the active site of Ezh2 in a canonical manner, with the side chain of methionine positioned in the lysine access channel, which provides mechanistic explanation for the high binding affinity of PRC2 by H3.3K27M mononucleosomes (Jiao and Liu, 2015; Justin et al., 2016) . In addition to the global loss of H3K27me3, we and others also observed that H3K27me3 peaks were detected at the promoters of hundreds of genes in DIPG xenograft cell lines (Bender et al., 2013; Chan et al., 2013b) . Strikingly, gene etiology analysis indicates that these genes associated with H3K27me3 in DIPG cells are enriched in cancer pathways (Chan et al., 2013b) . However, it is largely unknown how H3K37me3 are present at these specific genes in the environment of a 7 global loss of this mark. Moreover, the functional implications for the presence of H3K27me3 in tumorigenesis are also unexplored.
Here, we show that locus-specific retention of H3K27me3 in DIPG cells is a conserved phenomenon detected in two DIPG xenograft cell lines and one primary tumor sample.
Moreover, we provide two non-exclusive mechanisms for the locus-specific-retention of H3K27me3 in the environment of global loss in DIPG cells. First, H3.3K27M mutant proteins are low at these gene promoters. Second, Jarid2, a partner for the PRC2 complex, can relieve the inhibitory effect of H3.3K27M mutant proteins. Functionally, we show that H3K27me3 mediated silencing of tumor suppressor gene Wilms Tumor 1 (WT1) is required for the proliferation of DIPG cells.
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Results
H3K27me3 was detected in DIPG patient tissue and cell lines with H3.3K27M mutation
In addition to dramatic global reduction in H3K27 methylation as detected by Western blot and ChIP-seq assays, we also paradoxically observed the enrichment of H3K27me3 within the promoters of hundreds of genes in DIPG cell line (SF7761) harboring the H3.3K27M mutation (Chan et al., 2013b) . To determine whether the genes associated with H3K27me3 in SF7761 are also methylated in other DIPG tumor line and in primary DIPG tissue, we performed chromatin immunoprecipitation coupled with next-generation sequencing (ChIP-seq) in another DIPG xenograft cell line (SF8628), and one pontine glioma tissue sample with H3.3K27M mutation ( Figure S1A ). We identified 2,356 H3K27me3 ChIP-seq peaks in SF7761, 5,080 in SF8628 and 12,033 peaks in DIPG pontine tissue. When normalized against spike-in chromatin, the majority of these peaks exhibited reduced H3K27me3 levels. However, about 9% of H3K27me3 peaks in SF7761 and SF8682 and 6% of H3K27me3 in primary tissue exhibited similar or even higher levels of H3K27me3 peaks compared to their reference counterpart ( Figure S1B ). These results suggest that H3K27me3 peaks detected in DIPG cells are likely due to both the retention of H3K27me3 peaks in tumor-initiating cells as well as "gain" of H3K27me3 in tumor cells. In the rest of text, we did not address these two possibilities. Instead, we focus on analysis the mechanisms for the presence of H3K27me3 peaks and the functional consequence of these peaks for proliferation of DIPG cells.
Of all these H3K27me3 ChIP-seq peaks in two DIPG lines and one DIPG tissues, 1,088
H3K27me3 ChIP-seq peaks in SF7761, 2,729 in SF86828 and 3,431 in primary pontine tissue were localized at promoters. Importantly, 676 H3K27me3 peaks at/close to promoters 9 overlapped among these three samples ( Figure 1A-1B We also observed that 367 and 257 H3K27me3 peaks were in the vicinity of H3.3K27M mutant proteins in SF7761 and SF8628 cells, respectively ( Figure S2B -C, data not shown). When aligned at the peak center, H3K27me3 at the H3.3K27M centers were significantly lower than the surrounding regions ( Figure S2B -S2G). These results are consistent with the idea that the global loss of H3K27me3 is due to the inhibition by H3.3K27M mutant proteins. These results also suggest that other mechanism may exist to overcome the inhibition of H3.3K27M mutant proteins at these regions.
Depletion of Jarid2 results in a reduction of the residual H3K27me3 in DIPG cells
We made a serendipitous observation suggesting that Jarid2 is responsible for the presence of H3K27me3 peaks in cells expressing H3.3K27M mutant proteins, when we analyzed H3K27me3 levels in mES cells knocked in with a Flag-tagged H3.3K27M mutation (data not shown). To determine whether Jarid2 and Ezh2 are required for residual H3K27me3 in DIPG cells, we depleted Ezh2 and Jarid2 in two DIPG cell lines and observed a reduction of residual H3K27me3 by Western blot ( Figure 3A ). The reduction of H3K27me3 was also validated at two loci with Jarid2 and H3K27me3 through ChIP-PCR ( Figure 3B and S3A). Interestingly, we observed that depletion of Jarid2 led to reduction of Ezh2 at these two loci ( Figure 3C and S3B), whereas deletion of Ezh2 had no apparent effect on the binding of Jarid2 ( Figure 3D and S3C), consistent with the idea that Jarid2 is involved in recruiting Ezh2 to these loci for H3K27me3.
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Jarid2 is enriched at gene promoters with H3K27me3 in DIPG cells
Next, we tested whether Jarid2 is enriched at the promoters containing both H3K27me3 and H3.3K27M mutant proteins. To do this, we performed Ezh2 and Jarid2 ChIP-seq in SF7761 and These 4,195 H3K27me3 peaks were assumed to be present in tumor initiating cells" of SF8682 tumor before the introduction of H3.3K27M mutant proteins. Of these 4195 peaks, 331 gene promoters contained both H3K27me3 peaks in the "tumor initiating cells" and H3.3K27M ChIPseq peaks in SF8628 cells. Of these 331 peaks, we observed that 167 peaks overlapped with Jarid2 ChIP-seq peaks in SF8628 cells. We then compared H3.3K27M, Jarid2, H3K27me3, and Ezh2 ChIP-seq reads densities among the 331 peaks with (167) and without (164) Jarid2 ChIPseq peaks in SF8682 cells ( Figure 3E ). We observed that in SF8628 cells, the H3.3K27M ChIPseq reads density was similar between genes promoters associated and not associated Jarid2 ( Figure 3F ). In contrast, the H3K27me3 ( Figure 3G ) and Ezh2 ( Figure 3H ) were significantly higher at gene promoters with Jarid2 peaks than the ones without Jarid2 peaks. Similar results were obtained when we analyzed the relationships among Jarid2, Ezh2, H3.3K27M and 1 2
H3K27me3 levels in SF7761 cells (Figure S3E and S3F) . These results strongly suggest that the presence of Jarid2 can relieve the inhibition of PRC2 by H3.3K27M mutant proteins.
H3.3K27M peptide inhibits the activity of PRC2-Jarid2 complex less efficiently
To test whether Jarid2 can relieve the inhibitory effect of H3.3K27M on PRC2, we first compared the inhibitory effect of the H3K27M peptide on the enzymatic activity of recombinant PRC2 core complex in the presence or absence of Jarid2. As reported (Lewis et al., 2013) , the H3K27M peptide inhibited the enzymatic activity of core PRC2 complex towards mononucleosomes (IC50 = 73.2 ± 3.9 μM). Moreover, Jarid2 enhanced the enzymatic activity of the core PRC2 complex. Importantly, the H3.3K27M peptide exhibited a lesser inhibitory effect on the PRC2-Jarid2, with a 4.4 fold increase in IC50 compared to core PRC2 complex (IC50 = 256 ± 13.3 μM) ( Figure 4A -4C ). The corresponding H3 wild type peptide showed no obvious effects on the enzymatic activity of PRC2 with or without Jarid2. These results show that H3.3K27M mutant proteins inhibit the enzymatic activity of the Jarid2-PRC2 complex less efficiently.
One possibility for the reduced inhibition of Jarid2-PRC2 complex by H3.3K27M mutant proteins is because the Jarid2-PRC2 complex binds to H3.3K27M-containing nucleosomes less efficiently. To test this idea, we performed mononucleosome immunoprecipitation and analyzed the relative abundance of PRC2 core complex and Jarid2 that co-purified with H3.3K27M-and wild type H3.3-containing mononucleosomes using SILAC coupled to LC-MS/MS. We observed that Ezh2, EED, and Suz12 were similarly enriched on the H3.3K27M-containing mononucleosomes compared to wild type H3.3 mononucleosomes. In contrast, Jarid2 was not 1 3 ( Figure 4D ). The enrichment of Ezh2, but not Jarid2 on H3.3K27M mono-nucleosomes was confirmed by Western blot ( Figure S4 ). We noticed that another PRC2 core subunit, RbAp46/48, bound to wild type and mutant mononucleosome similarly, which is likely due to the fact that these two proteins are present in other chromatin complexes including CAF-1 (Verreault et al., 1996) and histone deacetylase complex NuRD (Xue et al., 1998; Zhang et al., 1999) . Together, these results support the idea that Jarid2 can relieve the inhibitory effect of H3.3K27M mutant proteins on PRC2 core complex.
Targeting Jarid2 to the H3.3K27M enriched loci leads to increased Ezh2 and H3K27me3 locally
To directly test the idea that Jarid2 can help overcome the H3.3K27M-mediated inhibition of PRC2 in cells, we used the CRISPR/dCas9 targeting system (Gilbert et al., 2013) to target Ezh2 or Jarid2 to two loci enriched with H3.3K27M, but with low levels of H3K27me3 in SF8628.
The dCas9 (dCas9-Flag), which lacks nuclease activity, was fused to Ezh2 (dCas9-Ezh2-Flag) or Jarid2 (dCas9-Jarid2-Flag) ( Figure S5A ). Five sgRNAs surrounding the PLXNA2 promoter were tested and one sgRNA with the highest targeting efficiency was selected for further experiments ( Figure S5B ). After transfection, the enrichments of Jarid2, Ezh2 and H3K27me3 at regions flanking the targeting site were analyzed by ChIP-PCR. Compared to dCas9-Flag, dCas9-Ezh2-Flag and dCas9-Jarid2-Flag appeared to show broad peaks surrounding the targeting site, suggesting that dCas9-Ezh2-Flag and dCas9-Jarid2-Flag can spread once targeted to this locus using CRISPR/dCas9 ( Figure 5A, upper panel) . Targeting Jarid2 to the PLXNA2 promoter resulted in an increase in both Ezh2 and H3K27me3 around the targeting loci ( Figure 5A , middle two panels), while having no apparent effect on the levels of H3.3K27M mutant proteins at the 1 4 PLXNA2 promoter ( Figure 5A, bottom panel) . In contrast, expression of dCas9-Ezh2-Flag fusion protein or dCas9-Flag proteins alone without sgRNA did not affect the levels of Jarid2 or H2K27me3 at the PLXNA2 promoter ( Figure 5A , S5C-S5F). Consistent with increased H3K27me3, targeting Jarid2, but not Ezh2, by CRISPR-dCas9 to the PLXNA2 promoter led to reduced expression of PLXNA2 compared to targeting dCas9 itself ( Figure 5B ). These results strongly support the idea that Jarid2 can recruit Ezh2 to regions with H3.3K27M and relieve the inhibitory effect of the mutant proteins.
Similar results were observed when targeting Jarid2 to an intergenic region associated with H3.3K27M mutant proteins. Targeting Jarid2 but not Ezh2 by CRISPR/dCas9 resulted in an increase of H3K27me3 and a reduction of H3K27ac surrounding the targeting site despite the fact that Ezh2 levels flanking the targeted region were detected in both cases ( Figure 5C-D) .
Control experiments that did not express sgRNAs did not show enrichment of Jarid2 or Ezh2 at the intergenic region nor changes in H3K27me3, Ezh2 and Jarid2 ( Figure S5C-S5E and S5G ).
Together, these results demonstrate that targeting Jarid2 can recruit Ezh2 to H3.3K27M enriched promoter and intergenic region, which leads to an increase in H3K27me3 at these sites.
Many putative tumor suppressor genes are silenced in DIPG cells through the H3K27me3-mediated mechanism
H3K27me3 is associated with gene silencing (Barski et al., 2007; Cao et al., 2002) . We hypothesize that the presence of H3K27me3 in DIPG cells represses the expression of tumor suppressor genes (TSGs). To test this idea, we first asked whether the 676 genes with H3K27me3 peaks in three samples(SF8628, SF7761 and the primary DIPG tissue) we analyzed 1 6 whereas depletion of Ezh2 had a less effect on H3K27me3 and Ezh2 levels at the promoter of WT1 despite the fact that depletion of Ezh2 led to reduced Ezh2 and H3K27me3 as determined by Western blot ( Figure 6D and Figure 3A) . These results indicate that Jarid2 and Ezh2 are involved in silencing of multiple TSGs in DIPG cells and that depletion of Jarid2 and Ezh2 have distinct effects on H3K27me3 levels at the WT1 promoter.
Depletion of Jarid2 and Ezh2 has a differential effect on cell growth
Next, we analyzed how depletion of Jarid2 and Ezh2 affected the proliferation of two H3.3K27M mutant cells ( Figure 6E ). We observed that the growth of SF7761 and SF8628 was inhibited by depletion of Jarid2. Depletion of Ezh2 by two independent shRNAs had minor effects in this short-term culture (Mohammad et al., 2017; Piunti et al., 2017) . In addition, depletion of Jarid2 and Ezh2 had no apparent effect on the growth of H3.3 wild type cells SF9427, despite the fact that the expressions of TSGs were activated in SF9427 cell line, suggesting that Jarid2 and Ezh2 mediated silencing of these TSGs is less critical for the proliferation of SF9427 line than two DIPG lines with the H3.3K27M mutation.
Forced expression of WT1 inhibits the proliferation of H3.3K27M mutant cells
WT1 was first discovered to be mutated in Wilms Tumor, a pediatric kidney tumor (Gessler et al., 1990; Huff, 1998; Maiti et al., 2000) . Since depletion of Jarid2 and Ezh2 had different effects on the expression of WT1 as well as proliferation, we asked whether forced expression of WT1 affected the proliferation of DIPG cells in a manner similar to Jarid2 depletion. We used two methods to increase WT1 expression. First, we overexpressed each of the four different isoforms of WT1 in H3.3K27M mutant cells (SF7761 and SF8628) and H3.3WT cells (SF9427), and
found that the expression of each WT1 isoform inhibited the proliferation of two H3.3K27M mutant cells, but not H3.3WT cells (SF9427) (Figure 7A and 7B), suggesting that silencing WT1 is more important for the proliferation of DIPG cells. Second, we tested whether alterations in chromatin states of the WT1 promoter by targeting p300 using CRISPR/dCas9 would also change the expression of WT1 and cell proliferation. We targeted dCas9-HA and dCas9-HA fused with p300 catalytic domain (dCas9-HA-p300-HA) to the WT1 promoter in SF8628 cells using two independent sgRNAs ( Figure S7A and S7B) . The dCas9-HA and dCas9-HA-p300-HA were enriched at the WT1 promoter only when they were co-expressed with either of the two sgRNAs, but not at the promoter of ACTIN ( Figure 7C , top panel). Targeting dCas9-HA-p300-HA to the WT1 promoter led to a reduction of H3K27me3, Ezh2 and Jarid2 as well as an increase in H3K27ac at the WT1 promoter, while having no apparent effect on the H3K27ac status of ACTIN promoter ( Figure 7C) . Moreover, the expression levels of WT1 increased through targeting dCas9-HA-p300-HA to the WT1 promoter ( Figure 7D) . Finally, the proliferation of SF8628 cells was inhibited when p300 catalytic domain was targeted to the WT1 promoter using CRISPR/dCas9 ( Figure 7E ). Together, these results show that alterations of chromatin states of WT1 promoter can change the expression of WT1 and proliferation of DIPG cells, supporting the idea that H3K27me3-mediated silencing of WT1 supports the proliferation of DIPG cells. 
Two mechanisms for the local retention of H3K27me3 in DIPG cells
Since the identification of H3.3K27M mutation in DIPG cells, we and others have shown that H3.3K27M mutant proteins drive the global loss of H3K27me3 on wild type histone proteins in part through its inhibitory effect on the enzymatic activity of the PRC2 complex (Bender et al., 2013; Chan et al., 2013b; Lewis et al., 2013) . In the environment of global loss of H3K27me3 in DIPG tumors, we and others also observed that H3K27me3 peaks were present at hundreds of loci based on analysis of H3K27me3 ChIP-seq (Bender et al., 2013; Chan et al., 2013b) . In this study, we further confirm the dichotomous changes of H3K27me3 in one additional DIPG xenograft line and one primary tumor. Importantly, we show that a significant number of gene promoters with H3K27me3 are common among three DIPG samples analyzed ( Figure 1B) , suggesting that the retention of H3K27me3 at these loci likely have a role in DIPG tumor cells.
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We have provided multiple lines of evidence supporting the idea that there are at least two mechanisms by which H3K27me3 is present at hundreds of loci in the environment of global loss. First, the levels of H3.3K27M mutant proteins at these loci with H3K27me3 are low compared to those without H3K27me3. The structure of PRC2 and H3.3K27M peptides reveals that methionine 27 is well accommodated by the hydrophobic side chains at the Ezh2 active site (Jiao and Liu, 2015; Justin et al., 2016) . The energy cost of de-solvating methionine from the active site is much higher than lysine, which explains the higher binding affinity of PRC2 with H3.3K27M mutant protein or peptide than the corresponding wild type one. Thus, H3.3K27M mutant proteins likely function as competitive inhibitors of the PRC2 enzyme. Consistent with this idea, replacement of other histone lysine residues to methionine such as H3 lysine 9 and histone H3 lysine 36 also inhibits enzymatic activity of their corresponding lysine methyltransferases (Fang et al., 2016; Jayaram et al., 2016; Lu et al., 2016; Shan et al., 2016) . In fission yeast, overexpression of Clr4, the H3K9 methyltransferase, overcomes the inhibition of H3K9M mutant proteins on H3K9me3 (Shan et al., 2016) . Thus, levels of H3.3K27M mutant proteins detected at most gene promoters with H3K27me3 may be insufficient to inhibit the enzymatic activity of PRC2 complex at these gene promoters.
Why then are the H3.3K27M mutant proteins low at these loci? H3.3 is assembled into nucleosomes in a replication-independent pathway (Ahmad and Henikoff, 2002b) . H3.3 ChIPseq in different cell lines reveals that H3.3 is enriched at actively transcribed genes compared to lowly expressed genes (Chow et al., 2005; McKittrick et al., 2004; Schübeler et al., 2004; Stroud et al., 2012) . We have shown that H3.3K27M mutant proteins exhibit a similar pattern of localization in two DIPG lines, suggesting that H3.3K27M mutant proteins are assembled into 2 0 nucleosomes in DIPG cells like WT H3.3. Therefore, the low levels of H3.3K27M mutant proteins at genes with H3K27me3 likely reflect the fact that the expression of these genes is low in tumor initiating cells for DIPG tumors.
In addition to the low levels of H3.3K27M mutant proteins, we also presented several lines of evidence supporting the idea that Jarid2, when formed a complex with the core PRC2 subunits, can target Ezh2 to the loci close to H3.3K27M mutant proteins and relieve the inhibitory effect of H3.3K27M mutant proteins. First, we show that at similar levels of H3.3K27M mutant proteins, H3K27me3 levels are high at promoter regions with Jarid2 compared to those without Jarid2 in DIPG cells. Second, H3.3K27M peptide inhibits the enzymatic activity of Jarid2-PRC2 complex less efficiently than PRC2 alone in vitro. Third, targeting Jarid2 to two chromatin loci with H3.3K27M mutant proteins leads to increased recruitment of Ezh2 and increased enrichment of H3K27me3. These results strongly support the model that Jarid2 overcome the inhibition of PRC2 activity by H3.3K27M mutant proteins. DIPG tumors occur primarily in mid-line brain structures and almost exclusively in children (Jones and Baker, 2014) , suggesting these tumors arise from a specific lineage of neuronal precursor within these regions (Funato et al., 2014) . We and others have shown that expression of H3.3K27M mutant proteins results in a global loss of H3K27 methylation, irrespective of celltype or organisms (Chan et al., 2013b; Herz et al., 2014; Lewis et al., 2013) . Therefore, the global reduction of H3K27 methylation in DIPG cells may not be the sole factor contributing to the tissue-and location-specific transformation observed in DIPG cells. Jarid2 can target PRC2 to specific chromatin loci and stimulate enzymatic activity of the PRC2 core complex. The 2 1 expression of Jarid2 is high in mES cells and is low in differentiated cells (Li et al., 2010) . Therefore, we propose that the tissue specific expression of Jarid2 can help locus-specific retention of H3K27 methylation and transform neuronal progenitor cells within mid-line regions into DIPG tumors.
Epigenetic silencing of TSGs contributes to the development of DIPG cells
Is there any function of the retention of H3K27me3 in DIPG cells? Since H3K27me3 is involved in gene silencing, we hypothesize that retention of H3K27me3 in DIPG cells may help silence TSGs. Indeed, we observed that over 80 putative TSGs have high levels of H3K27me3 at their promoters in all three DIPG samples tested. It is known that inactivation of TSGs by genetic and epigenetic means is important for both tumor initiation and proliferation of tumor cells (Dawson and Kouzarides, 2012; Nephew and Huang, 2003; Riley and Anderson, 2011) . In this study, we focus on identifying genes that when silenced are involved in proliferation of DIPG cells. We show that forced expression of WT1 either using a plasmid or alterations of chromatin state of WT1 endogenous promoter inhibit the proliferation of DIPG cells. These results strongly indicate that H3K27me3-mediated epigenetic silencing of WT1 is important for the proliferation of DIPG cells. WT1 is a zinc finger transcription factor (Bardeesy and Pelletier, 1998) . It was first identified as a TSG in Wilms tumor, a tumor also found exclusively in children (Gessler et al., 1990; Maiti et al., 2000) . Accumulating evidence suggests that WT1 is also expressed in many different classes of intracranial tumors, including gliomas (Izumoto et al., 2008) , oligodendrogliomas (Rauscher et al., 2014) , ependymomas (Yeung et al., 2013) , and meningiomas (Iwami et al., 2013) and functions as an oncogene during tumor initiation and 2 2 progression of these tumors. Therefore, it is interesting that WT1 functions as a TSG that modulates the proliferation of DIPG cells.
In addition to WT1, other TSGs including cell cycle inhibitors p16 and p15 also contain H3K27me3 at their promoters and are expressed at low levels in DIPG cells. Moreover, depletion of Jarid2 and Ezh2 also results in increased expression of 5 TSGs out of 12 genes tested. These results indicate that these genes are also silenced through the H3K27me3-mediated mechanism. We propose that H3K27me3-mediated silencing of TSGs likely contributes to the initiation and maintenance of DIPG tumors despite the fact that H3K27me3 is reduced globally.
Consistent with this idea, inactive mutations at Ezh2, catalytic subunit of PRC2, have not reported despite the fact that many DIPG tumor samples have been sequenced. Therefore, we propose that it is the dichotomous changes in H3K27me3, including both global loss and locusspecific retention/gain of H3K27me3 in H3K27me3 in DIPG cells contribute to tumorigenesis.
The dichotomous change in H3K27me3 in DIPG cells is reminiscent of DNA methylation alteration observed in many cancer cells (Baylin and Jones, 2011) . It is known for a long time that genomic DNA in most cancer cells is hypomethylated (Eden et al., 2003; Ehrlich, 2009) , and yet DNA hypermethylation at TSGs has been frequently reported in many cancer types (Baylin, 2005; Esteller, 2007; Struhl, 2014) . DNA methylation analysis in DIPG cells also indicates that DNA is hypomethylated (Bender et al., 2013) . It would be interesting to determine whether DNA is hypermethylated at TSG genes or any genes with high levels of H3K27 methylation in the future.
3
In summary, we have shown that H3K27me3 is detected in two DIPG cells and one primary DIPG tissue, and a large number of gene promoters with H3K27me3 are the same among these three samples. The presence of H3K27me3 at these gene promoters is due to low levels of H3.3K27M mutant proteins and/or the formation of Jarid2-PRC2 complex, which can relieve the inhibitory effect of H3.3K27M mutant proteins. Finally, we show that H3K27me3-mediated silencing of WT1 is required for the proliferation of DIPG cells. These results indicate that inhibition of Ezh2 may also be an option for the treatment of DIPG tumors in the future. Figure S3D ). These 331 genes were sub-grouped based on Jarid2 ChIP-seq peaks in SF8628 cells, and Log 2 normalized reads density for Jarid2 (E), H3.3K27M (F), H3K27me3 (G), and Ezh2 (H) at the promoters with (+Jarid2) or without (-Jarid) Jarid2 ChIP-seq peaks were calculated and shown as Boxplot. P value was calculated by two-tailed Student's t test. N.S. Not Significant. SF8628 cell proliferation is inhibited by targeting dCas9-HA-p300-HA to the WT1 promoter.
Data are mean ± SD (N = 3 independent replicates, **P < 0.01). 
